Skip to main content
Terug
TGRNF logo

Tong Ren Tang Technologies Co. Ltd.

Datakwaliteit: 100%
Oversold
TGRNF
OTC Healthcare Drug Manufacturers - General
€ 0,55
€ 0,00 (0,00%)
Marktkapitalisatie: 704,42M
Dagbereik
€ 0,55 € 0,55
52-Weeksbereik
€ 0,55 € 0,70
Volume
1.000
50D / 200D Gem.
€ 0,69 / € 0,67
Vorige Slotkoers
€ 0,55

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 1,4 0,3
P/B 0,1 2,9
ROE % 7,4 3,7
Net Margin % 7,2 3,8
Rev Growth 5Y % 12,0 10,0
D/E 0,3 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 € 0,51
€ 0,51 – € 0,51
 8,7 B 1
FY2026 € 0,46
€ 0,46 – € 0,46
 8 B 1

Belangrijkste Punten

Revenue grew 12,04% annually over 5 years — strong growth
Earnings declined -11,59% over the past year
Debt/Equity of 0,34 — conservative balance sheet
Negative free cash flow of -158,56M
P/E of 1,35 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 4,86%

Groei

Revenue Growth (5Y)
12,04%
Revenue (1Y)7,18%
Earnings (1Y)-11,59%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
7,40%
ROIC7,67%
Net Margin7,19%
Op. Margin13,57%

Veiligheid

Debt / Equity
0,34
Current Ratio3,81
Interest Coverage15,28

Waardering

P/E Ratio
1,35
P/B Ratio0,10
EV/EBITDA-1,01
Dividend Yield0,04%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 7,18% Revenue Growth (3Y) 10,07%
Earnings Growth (1Y) -11,59% Earnings Growth (3Y) -5,39%
Revenue Growth (5Y) 12,04% Earnings Growth (5Y) 2,78%
Profitability
Revenue (TTM) 7,26B Net Income (TTM) 521,80M
ROE 7,40% ROA 3,62%
Gross Margin 39,64% Operating Margin 13,57%
Net Margin 7,19% Free Cash Flow (TTM) -158,56M
ROIC 7,67% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,34 Current Ratio 3,81
Interest Coverage 15,28 Dividend Yield 0,04%
Valuation
P/E Ratio 1,35 P/B Ratio 0,10
P/S Ratio 0,10 PEG Ratio -1,13
EV/EBITDA -1,01 Dividend Yield 0,04%
Market Cap 704,42M Enterprise Value -999,86M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 7,26B 6,77B 5,99B 5,40B 4,61B
Net Income 521,80M 590,19M 582,89M 507,25M 467,55M
EPS (Diluted) 0,41 0,46 0,46 0,40 0,37
Gross Profit 2,88B 2,85B 2,59B 2,29B 2,07B
Operating Income 985,16M 1,12B 1,21B 1,08B 943,55M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 14,41B 13,51B 12,48B 11,59B 10,94B
Total Liabilities 4,24B 3,86B 3,47B 3,44B 3,19B
Shareholders' Equity 7,21B 6,89B 6,48B 5,98B 5,73B
Total Debt 2,43B 1,63B 1,59B 1,64B 1,69B
Cash & Equivalents 4,13B 2,75B 3,72B 3,25B 2,95B
Current Assets 10,83B 10,06B 9,07B 8,13B 7,45B
Current Liabilities 2,84B 2,24B 2,05B 2,46B 2,45B

Strategiescores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Growth Price/Sales Ratio Focus (Ken Fisher)
#543 of 618
12
Value Defensive Investing (Benjamin Graham)
#234 of 709
37

Recente Activiteit

Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026